Vascular lesion treatment IPL system OptiLIGHT

dry eye treatmenttable-top

Overview
OptiLIGHT is an IPL medical device designed for the management of dry eye disease associated with Meibomian Gland Dysfunction (MGD). The system integrates patented Optimal Pulse Technology (OPT™) with clinician‑focused ergonomics and embedded treatment protocols. It is indicated as an adjunctive light‑based therapy in appropriate patients and is FDA‑cleared for management of DED due to MGD in specified indications.

Key benefits and clinical outcomes
OptiLIGHT targets multiple drivers of evaporative dry eye and delivers measurable clinical effects:

• Reduces inflammatory mediators in the tear film (reports of decreased IL‑6, IL‑17).
• Improves tear film stability and increases tear breakup time (clinical studies report near‑doubling of TBUT).
• Restores meibomian gland morphology and improves gland function.
• Addresses periocular telangiectasia and abnormal vessels that perpetuate inflammation.
• Reduces Demodex counts on the lid margin and decreases bacterial load.

Procedure and practice integration
Each treatment session lasts approximately 15 minutes. Typical treatment course: four sessions. Workflow is configured for rapid chairside use and integration into ophthalmic or optometric practice with eyes fully occluded during light application.

Device design and components
The system combines the following elements designed for clinical use:

• Patented OPT™ (Optimal Pulse Technology) for uniform, controlled energy delivery.
• OPT™ handpiece engineered to adapt to facial contours.
• Ergonomic IPL handpiece with continuous contact cooling (SapphireCool™).
• Opti‑Tip lightguides for targeted, hygienic energy application (multiple sizes).
• Embedded, clinically validated settings and treatment protocols.

Indications
Indicated for management of dry eye disease due to Meibomian Gland Dysfunction (MGD). Regional indications:

• EU: evaporative DED due to MGD (intended for Fitzpatrick skin types I–V).
• US: improvement of signs of DED due to MGD in patients ≥22 years with moderate to severe signs and Fitzpatrick skin types I–IV; IPL applied to the malar region with ocular occlusion; used as adjunct to other modalities (meibomian gland expression, artificial tears, warm compresses).

Contraindications and possible side effects
Contraindications and precautions include (non‑exhaustive):

• Ocular or eyelid surgery or neuro‑paralysis within 6 months prior to treatment.
• Uncontrolled ocular surface disease, infections, or immunosuppressive conditions.
• Pre‑cancerous lesions, skin cancer, or pigmented lesions in the treatment area.
• Recent ocular infections, recent head/neck radiation, or planned radiation therapy.
• Recent or planned chemotherapy; use of photosensitizing medications/herbs within 3 months prior to first IPL session.
• History of herpes simplex, systemic lupus erythematosus, porphyria, migraine with photosensitivity, seizures or epilepsy (may require caution or exclusion).

Reported adverse events following IPL may include pain/discomfort, changes in skin texture or pigmentation, scarring, edema, bruising, burns, pruritus and xerosis.

Clinical evidence
Peer‑reviewed studies conducted with Lumenis IPL using OPT technology report reductions in inflammatory markers (e.g. IL‑6, IL‑17), improvements in tear breakup time and other objective and subjective measures. References are provided in the product documentation.

Features (summary)

• OPT™ handpiece and OPT™ technology for consistent, controlled pulses.
• Ergonomic IPL handpiece with continuous contact cooling (SapphireCool™).
• Opti‑Tips/lightguides in multiple sizes for targeted application (15×35 mm, 8×15 mm, Ø6.4 mm).
• Clinically validated, embedded treatment protocols.
• Typical session duration ~15 minutes; standard course: 4 sessions.

Characteristics / Technical specifications

• System wavelength range with 590 nm cut‑off filter: 590–1200 nm (general IPL range noted 400–1200 nm with system filtering).
• Selectable filters and ExpertFilters with example ranges for acne and vascular indications; individual filter options include 515, 560, 590, 615, 640, 695, 755 nm.
• Lightguide sizes: 15×35 mm, 8×15 mm, Ø6.4 mm.
• Maximal fluence (noted for upgraded aesthetic configuration): up to 35 J/cm².
• Continuous contact cooling (SapphireCool™) and ergonomic handpiece design.